NC
BMRN icon

North Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

North Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51
Closed -$2.76K – 157
2025
Q3 		$2.76K Buy
51
+1
+2% +$57 ﹤0.01% 492
2025
Q2 		$2.75K Hold
50
– – ﹤0.01% 485
2025
Q1 		$3.54K Buy
+50
New +$3.36K ﹤0.01% 458

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

North Capital's BMRN Position: Q4 2025 in Review

North Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 51 shares — an estimated $2.76K sold.

North Capital first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $3.54K in Q1 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • North Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • North Capital sold 51 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $2.76K.
  • North Capital first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • North Capital's BioMarin Pharmaceuticals position peaked at $3.54K in Q1 2025.
  • 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on North Capital's 13F filing for Q4 2025, filed 18 Feb 2026.